DESLORATADINE ALLERGY CONTROL TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

DESLORATADINE

Sẵn có từ:

DOMINION PHARMACAL

Mã ATC:

R06AX27

INN (Tên quốc tế):

DESLORATADINE

Liều dùng:

5MG

Dạng dược phẩm:

TABLET

Thành phần:

DESLORATADINE 5MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

10/20/30/50/70

Loại thuốc theo toa:

OTC

Khu trị liệu:

SECOND GENERATION ANTIHISTAMINES

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0143961001; AHFS:

Tình trạng ủy quyền:

CANCELLED POST MARKET

Ngày ủy quyền:

2020-05-06

Đặc tính sản phẩm

PRODUCT MONOGRAPH
DESLORATADINE ALLERGY CONTROL
Desloratadine tablets
5 mg
Histamine H
1
-Receptor Antagonist
DOMINION PHARMAC
A
L
6111 Royalmount Avenue, Suite 100
Montreal, Quebec
H4P 2T4
Date of Preparation:
July 10, 2017
Submission Control No.: 206132
_DESLORATADINE ALLERGY CONTROL _
_Page 2 of 36_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
..........................................................................................11
SPECIAL HANDLING INSTRUCTIONS
.......................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................11
PART II: SCIENTIFIC INFORMATION
...............................................................................12
PHARMACEUTICAL INFORMATION
..........................................................................12
CLINICAL TRIALS
...........................................................................